Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

por Suh, Chang-Hee, Yoo, Dae Hyun, Berrocal Kasay, Alfredo, Chalouhi El-Khouri, Elia, Cons Molina, Francisco Fidenci, Shesternya, Pavel, Miranda, Pedro, Medina-Rodriguez, Francisco G., Wiland, Piotr, Jeka, Slawomir, Chavez-Corrales, Jose, Linde, Thomas, Hrycaj, Pawel, Abello-Banfi, Mauricio, Hospodarskyy, Ihor, Jaworski, Janusz, Piotrowski, Mariusz, Brzosko, Marek, Krogulec, Marek, Shevchuk, Sergii, Calvo, Armando, Andersone, Daina, Park, Won, Shim, Seung Cheol, Lee, Sang Joon, Lee, Sung Young
Publicado 2019

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

por Park, Won, Božić-Majstorović, Ljubinka, Milakovic, Dragana, Berrocal Kasay, Alfredo, El-Khouri, Elias Chalouhi, Irazoque-Palazuelos, Fedra, Molina, Francisco Fidencio Cons, Shesternya, Pavel, Miranda, Pedro, Medina-Rodriguez, Francisco G., Wiland, Piotr, Jeka, Slawomir, Chavez-Corrales, Jose, Garmish, Olena, Linde, Thomas, Rekalov, Dmytro, Hrycaj, Pawel, Krause, Andreas, Fomina, Natalia, Piura, Olena, Abello-Banfi, Mauricio, Suh, Chang-Hee, Shim, Seung Cheol, Lee, Sang Joon, Lee, Sung Young, Kim, Sung Hwan, Yoo, Dae Hyun
Publicado 2018